Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

AZTR US Equity

Azitra, Inc.Health Care · Pharmaceutical Preparations · CIK 1701478 · FY ends Dec 31
$0.13
+0.00 (+0.16%)
USD · as of 2026-08-19 · marketstack

Legal & controls

3 of 3 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-02-27described hereNOT effectiveNOT effectivedisclosedEDGAR

Item 3 · As of the date of this report, there are no legal proceedings to which we or our properties are subject. We may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes and are not predictable with assurance.

Item 9A · ICFR · Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2025, and based on that evaluation, management concluded that our internal control over financial reporting were not effective as of December 31, 2025 due to a material weakness relating to a lack of segregation of accounting functions.

Item 9A · disclosure controls · Based upon the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective as of December 31, 2025.

Item 9A · material weakness · In the course of that evaluation, we identified a material weakness as it relates to a lack of adequate segregation of accounting functions.

2024-12-312025-02-24described hereNOT effectiveNOT effectivedisclosedEDGAR

Item 3 · As of the date of this report, there are no legal proceedings to which we or our properties are subject. We may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes and are not predictable with assurance.

Item 9A · ICFR · Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024, and based on that evaluation, management concluded that our internal control over financial reporting were not effective as of December 31, 2024 due to a material weakness relating to a lack of segregation of accounting functions.

Item 9A · disclosure controls · Based upon the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective as of December 31, 2023.

Item 9A · material weakness · In the course of that evaluation, we identified a material weakness as it relates to a lack of adequate segregation of accounting functions.

2023-12-312024-03-15described herenot extractedNOT effectivedisclosedEDGAR

Item 3 · As of the date of this report, there are no legal proceedings to which we or our properties are subject. We may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes and are not predictable with assurance.

Item 9A · disclosure controls · Based upon the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective as of December 31, 2023.

Item 9A · material weakness · In the course of that evaluation, we identified a material weakness as it relates to a lack of adequate segregation of accounting functions.

3 of 3 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.